Tobam grew its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 284.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,528 shares of the company’s stock after acquiring an additional 53,659 shares during the period. Tobam’s holdings in Johnson & Johnson were worth $11,848,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently made changes to their positions in the business. Morton Brown Family Wealth LLC boosted its holdings in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $39,000. Cardinal Capital Management Inc. increased its stake in Johnson & Johnson by 333.3% in the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares during the last quarter. First Bank & Trust raised its holdings in shares of Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after acquiring an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $84,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have commented on the stock. Sanford C. Bernstein lowered their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Morgan Stanley reduced their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 6th. StockNews.com initiated coverage on Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Barclays began coverage on Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Finally, Credit Suisse Group began coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective on the stock. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.
Johnson & Johnson Trading Down 0.3 %
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.
In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 233,611 shares of company stock valued at $40,960,735. Corporate insiders own 0.35% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.